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Background: Fecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile
infection (CDI) that often fails standard antibiotic therapy. Despite its widespread recent use, however, little is
known about the stability of the fecal microbiota following FMT.
Results: Here we report on short- and long-term changes and provide kinetic visualization of fecal microbiota
composition in patients with multiply recurrent CDI that were refractory to antibiotic therapy and treated using
FMT. Fecal samples were collected from four patients before and up to 151 days after FMT, with daily collections
until 28 days and weekly collections until 84 days post-FMT. The composition of fecal bacteria was characterized
using high throughput 16S rRNA gene sequence analysis, compared to microbiota across body sites in the Human
Microbiome Project (HMP) database, and visualized in a movie-like, kinetic format. FMT resulted in rapid normalization
of bacterial fecal sample composition from a markedly dysbiotic state to one representative of normal fecal microbiota.
While the microbiome appeared most similar to the donor implant material 1 day post-FMT, the composition diverged
variably at later time points. The donor microbiota composition also varied over time. However, both post-FMT and
donor samples remained within the larger cloud of fecal microbiota characterized as healthy by the HMP.
Conclusions: Dynamic behavior is an intrinsic property of normal fecal microbiota and should be accounted for in
comparing microbial communities among normal individuals and those with disease states. This also suggests
that more frequent sample analyses are needed in order to properly assess success of FMT procedures.
Keywords: Short- and long-term changes in microbiota following FMTBackground
Fecal microbiota transplantation (FMT) has emerged in
recent years as a highly effective treatment for refractory
Clostridium difficile infection (CDI) that cannot be
cured with antibiotics alone [1]. The procedure leads to
prompt engraftment of donor microbiota, attainment of* Correspondence: sadowsky@umn.edu
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overall microbial community structure [2-8]. However,
existing data characterizing long-term stability of engrafted
microbiota are limited. One recent study suggests the
microbiota of patients after FMT may not fully recover
until 16 weeks after the procedure [9]. This type of ana-
lysis, however, is complicated by the fact that the microbial
communities are intrinsically dynamic and affected by daily
fluctuations in the host’s diet, activities, and health [10-12].
In addition, multiple fixed host factors, such as different
states of immune competence, genetics, or gastrointestinal
anatomy, likely also affect the composition, stability, orntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Fecal bacterial communities of recurrent CDI patients
shift towards HMP fecal bacterial communities after FMT.
Pre-FMT patient samples (red circle); post-FMT patient samples (green
circles); trajectory of patient fecal communities after FMT (blue line).
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unclear whether divergence in post-FMT microbiota
from that of donor implant material represents contin-
ued recovery, or whether these temporal changes are a
general characteristic of host-associated gut microbiota
in a changing host environment.
Here we describe both short- and long-term dynamic
changes of fecal bacterial composition in four patients
following FMT. All patients received microbiota from
the same pre-qualified donor according to the standard-
ized FMT protocol we described previously [18]. Three
patients received freshly prepared microbiota and one
patient received microbiota that had previously been
frozen. We compared pre- and post-FMT fecal micro-
bial communities from these patients, as well as pre-
FMT communities from 10 additional patients with
multiply recurrent CDI (R-CDI), to the sequences of
normal subjects described in the Human Microbiome
Project [19]. In addition, we compared temporal changes
in fecal bacterial composition in recipients following
FMT to temporal changes observed within samples
from the donor.
Results
Bacterial composition of fecal samples from patients with
recurrent CDI becomes healthy and donor-like following FMT
Four patients (CD1 to CD4) with recurrent CDI were
treated with FMT using material obtained from a single
donor but from different time points, and fecal samples
were collected from these patients before and after the
procedure as well as from the donor at times of dona-
tion. Bacterial communities from these fecal samples
were characterized by sequencing the V4 region of the
16S rRNA gene. Following trimming and quality filter-
ing from a total of 12,536,492 sequences, we randomly
subsampled to 5,000 sequences/sample in order to
normalize read depth across all samples. All further
analyses were performed using this rarefied read depth.
To better understand changes in bacterial communities
following FMT, we compared the bacterial composition of
patient fecal samples to those of microbial communities
from various body sites from the 252 healthy individuals
characterized in the Human Microbiota Project (HMP)
[19] (Figure 1) using unweighted UniFrac [20] followed by
principal coordinates analysis (PCoA) [21] (see Additional
file 1: Movie supplement). The composition of pre-FMT
fecal samples from patients CD1 to CD4 and 10 additional
patients with recurrent CDI was distinct from both fecal
samples from healthy individuals and microbial communi-
ties at other body sites, including mouth, vagina, and
skin, demonstrating severe alterations in pre-FMT com-
munities compared to healthy fecal communities as has
been previously shown [4,5]. In contrast, microbial
communities from the donor fell within the range ofhealthy fecal samples. Using an animated visualization
of FMT-associated changes in patients’ fecal microbial
communities, we observed rapid and dramatic shifts
after FMT towards the communities found in the feces
of healthy individuals and of the original donor (see
Additional file 1: Movie supplement).
Fecal microbial communities remain dynamic following FMT
To more closely examine temporal changes in recipient
fecal samples following FMT, we analyzed fecal microbial
communities from patients CD1 to CD4 and donor, as
well as from 10 additional donor samples, using weighted
and unweighted UniFrac [20] followed by PCoA [21]. This
analysis demonstrated that fecal bacterial communities
continued to undergo compositional fluctuation following
FMT (Figure 2A and Additional file 2: Figure S1; individ-
uals OTUs listed in Additional file 3: Table S1).
To determine whether this dynamic range of post-
FMT microbial composition fits within the range seen
across healthy individuals, we also compared communi-
ties in our samples to those in the HMP via weighted
UniFrac and PCoA (Figure 2B). Again, fecal microbial
communities prior to FMT were highly distinct from
healthy fecal microbial communities, and following the
procedure, these communities more closely resembled
those of healthy individuals. Similar to the comparison
with donor communities above, fecal microbial communi-
ties of recurrent CDI patients following FMT shifted within
the cluster of communities from healthy individuals.
Rapid and substantial changes to Enterobacteriales in
feces following FMT
While overall fecal microbial communities were dramat-
ically altered following FMT, we also examined the


















Figure 2 Microbial communities shift following FMT. (A) Unweighted (left) and weighted (right) UniFrac analyses followed by principal
component analysis of bacterial communities of recurrent CDI patient fecal samples before (red) and after FMT and donor samples (blue). (B)
Weighted UniFrac analysis followed by principal component analysis of bacterial communities of patients before (red) and after FMT versus HMP
fecal communities (purple). PC, principal component. Percentages represent percent variability explained by each principal component. Se key at
right for colors associated with samples before FMT (pre-FMT), from HMP and donor, and from patients after FMT (CD1 to CD4).
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patients. As shown previously [2-8], the relative abun-
dance of bacterial phyla in patient fecal samples shifted
substantially following FMT, with relative decreases in
Proteobacteria and relative increases in Bacteroidetes
and Firmicutes (Figure 3). These Proteobacteria are
primarily the order Enterobacteriales, which were also
substantially decreased in relative abundance following
FMT (Figure 4A).
We focused on these changes by examining the rela-
tive abundance of Enterobacteriales alone in each patient
before and after FMT. The relative abundance of this
taxon ranged from 44% to 82% in all four patient sam-
ples prior to FMT and rapidly dropped to undetectable
levels within 1 week after the procedure. Moreover,
abundance of this taxon remained low at 26 days after
FMT, the latest time point shared by all four patients
(Figure 4A), although other members of the Proteobac-
teria remain detectable if decreased in relative abun-
dance (Figure 3). In addition, we generated individual
value control charts based on the average abundance of
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Figure 3 Changes in fecal microbial communities after FMT. Relative a
and after FMT in patient fecal samples. Samples after FMT indicated with drelative abundance, these control charts displayed the
expected variation of the abundance of Enterobacteriales
in these fecal samples. In all patients, the abundance of
Enterobacteriales was above the expected variation (that
is, more than three standard deviations above the mean
relative abundance [the standard upper control limit, or
UCL] of this order across all samples) prior to FMT, and
rapidly fell below the upper control limit within 1 to 2
days after the procedure (Figure 4B). These results sug-
gest that the relative abundance of Enterobacteriales
significantly decreased in all patients soon after FMT to
levels similar to donor samples and remained within a
statistically expected range for the duration of sample
collection (up to 151 days post-FMT).
Post-FMT communities are initially similar to donor
samples but can later diverge
Next, we compared fecal microbial communities within
each patient over time to that of the initial donor sample.
We generated heat maps based on Pearson correlations
between every sample within a given patient set, including

















bundance of sequences classified to the level of bacterial phyla before
ashed line. See key at right.
Figure 4 Changes in the order Enterobacteriales after FMT. (A) Relative abundance of Enterobacteriales in donor and patient samples before
and after FMT in samples common across all patients. (B) Control charts of relative abundance of Enterobacteriales in donor (leftmost sample) and
patient samples before and after FMT. Patient CD1 (top left), patient CD2 (top right), patient CD3 (bottom left), patient CD4 (bottom right). LCL,
lower control limit; UCL, upper control limit; mean relative abundance in all samples (center). LCL and UCL represent three standard deviations in
relative abundance below and above the mean, respectively. Dashed lines indicate samples after FMT.
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while microbiota in samples from patients after FMT
quickly became similar to microbiota in donor samples,
the similarity of samples taken at later time points after
FMT fluctuated.
To further investigate how fecal microbial communi-
ties in these patients correlate to donor communities,
we examined Pearson and Spearman correlations be-
tween donor and patient samples, which were common
to each patient (pre-FMT samples and those up to 26 days
post-FMT; Figure 5B,C and Additional file 4: Figure S2).
While fecal microbial communities from patients beforeFigure 5 Pearson and Spearman correlations between fecal communi
values between each sample within each patient set, corresponding donor
correlation values between donor sample and each patient sample. (C) Spe
(D) Heat maps of Pearson (i) and Spearman (ii) correlation values between
collection time of each sample versus earliest donor sample. CD1 to CD4, pFMT were highly distinct from those in the donor, fecal
microbial communities from samples 1 day after the
procedure were highly correlated to donor communities
via both Pearson and Spearman analyses in all patients.
After the initial time point after FMT, the Pearson cor-
relation values of patient to donor samples were highly
variable within and across patients, although Spearman
correlations remained high for three patients. To exam-
ine whether this variation is similar in healthy individ-
uals, we determined Pearson and Spearman correlations
within the four donor samples used in FMT, as well as
eight additional donor samples from the same individualties before and after FMT. (A) Heat map of Pearson correlation
, and 10 additional pre-FMT patient samples (far right). (B) Pearson
arman correlations between donor sample and each patient sample.
earliest donor sample and eleven subsequent samples; days represent
atients 1 to 4. Dashed lines indicate samples after FMT.
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microbiota also changed over time (Figure 5D). These
findings suggested that the level of variability seen across
patient post-FMT fecal microbial communities was within
the range of normal microbiota behavior in a healthy
individual.
Normalization and dynamic range of post-FMT patient fecal
microbial communities are similar to donor communities
Because of the observed variability in later post-FMT
patient fecal communities relative to single donor com-
munities, we compared the communities of these pa-
tient samples to an expanded set of 17 samples taken from
the same donor. We generated two metrics to evaluate the
relationships between these communities: normalization
and dynamic range (stability). Normalization refers to the
mean between-sample distance for each set of patient
samples versus the set of donor samples, while dynamic
range is the mean distance between each sample within
a single patient set. Effectively, the normality of a post-
FMT patient sample set is a measure of how similar it is
to the donor (healthy) sample set, while dynamic range
is a measure of variability within a given patient sample
set. We found that neither the normalization nor the
dynamic range of any post-FMT patient sample set was
significantly different than the donor set following
analysis using unweighted UniFrac (Table 1). This
suggested that although fecal microbial communities of
patients post-FMT do not remain identical to the donor,
they nonetheless fall within expected parameters rela-
tive to the healthy donor. Similar results were obtained
when these analyses were repeated with other parame-
ters, including weighted UniFrac, Jensen-Shannon and
root Jensen-Shannon, and Bray-Curtis (data not shown).
Discussion
It is now well understood that the fecal microbiota
change substantially following FMT, typically shifting to
fecal microbial communities more similar to those of the
donor after transplant [2-8]. Here we show that these
communities shift away from a dysbiotic state towards a
composition that is representative of fecal microbial com-
munities from hundreds of healthy individuals, collected
in the HMP [19]. Similarly to previous studies [4-8], the
dysbiotic state in these patients with multiply recurrentTable 1 P values of normalization and dynamic range of
patient samples sets versus donor set




CD4 0.484 0.473CDI is characterized by a large expansion of Proteobac-
teria (primarily members of the order Enterobacteriales,
which contains the family Enterobacteriaceae), and FMT
is associated with reemergence of dominance by members
of the Bacteroidetes and Firmicutes phyla.
Analysis of multiple donor and post-FMT samples
demonstrates the dynamic behavior of fecal microbial
communities over time. Both donor and recipient sam-
ples are characterized by highly dynamic shifts that
nonetheless remain within the compositional range of
normal fecal microbiota. This observation is consistent
with known rapid responsiveness of the fecal micro-
biome to environmental inputs, such as dietary varia-
tions [11], and drifts in microbiota composition over
time in healthy individuals [22].
The dynamic nature of intestinal microbiota is an in-
trinsic property, which should be taken into account
when considering how therapeutic interventions, includ-
ing FMT, impact its composition over time. In long-term
post-FMT follow-up, Song and colleagues also noted dy-
namic changes in the fecal microbiome of R-CDI patients
up to 16 weeks post-FMT [9]. These investigators con-
cluded that the fecal microbiome of post-FMT patients
did not fully recover over this time, despite clinical recov-
ery. Indeed, we observed divergence of microbiome in
some of the patients away from the original implanted
material over time. However, analysis of multiple donor
samples showed that this movement is within the same
dynamic range observed in the donor’s fecal micro-
biome. We therefore conclude that the dynamic behavior
of microbiota needs to be taken into account in making
comparisons between individuals, and should become an
integral part of analysis of the success of FMT.
Three of the recipients in this study received freshly
prepared microbiota, while one received frozen/thawed
preparation. Use of frozen microbiota preparations is in-
creasing in clinical practice [23], and its equivalency has
not been rigorously established in randomized clinical
trials. The ability to store microbiota allows the most
up-to-date testing of the donor and fecal material for
infectious pathogens, as some of the current tests may
take several weeks to complete. Therefore, ability to
preserve donor microbiota long-term is critical for its
development as a therapeutic agent in clinical practice.
Our results here, although limited in the number of pa-
tients, demonstrate indistinguishable behavior of fresh
and frozen/thawed microbiota preparation.
The patients in this study did not have any significant
gastrointestinal comorbidities. However, a significant
proportion of patients with recurrent CDI have under-
lying inflammatory bowel disease, take potent immuno-
suppressive medications, or have multiple other medical
problems [18,24]. The importance of these host factors
in contributing to microbiota behavior is currently
Weingarden et al. Microbiome  (2015) 3:10 Page 6 of 8unknown, but is a subject of great interest [25]. Under-
standing these influences will require analysis of multiple
samples. Recently, Fuentes and colleagues [8] reported
that some specific microbial groups and interactive
networks are likely to be very important for the main-
tenance of microbiota in healthy individuals. However,
although there is a great deal of effort focused on
discovery of compositional differences in microbiota be-
tween normal subjects and individuals with different
gastrointestinal and medical conditions, the dynamic
behavior of fecal microbiota constitutes another dimen-
sion that may distinguish these cases. Thus, predictors
of stable or dysbiotic intestinal microflora may also
change over time. Further detailed studies of dynamic
behavior of post-FMT microbiota may improve our
understanding of causal connections between microbial
communities and different disease states.
Conclusions
The fecal microbiota of patients with R-CDI continues
to undergo change after FMT is performed, though
these changes appear to fall within the range of normal
variation of healthy individuals over time. Dynamic be-
havior is an intrinsic property of normal fecal microbiota
and should be accounted for in comparing microbial




All patients suffered from multiply recurrent CDI refrac-
tory to standard antibiotic therapies. A single standard
donor was used in the preparation of all fecal microbiota
material as described previously [18]. The Institutional
Review Board at the University of Minnesota approved
prospective collection of fecal specimens and their
analysis. All patients satisfied the inclusion criteria for
the FMT within our program, which included at least
two spontaneous recurrences of CDI within a month of
discontinuation of antibiotics and failure of at least one
advanced antibiotic regimen such as a vancomycin
pulse/taper protocol or vancomycin treatment followed
by administration of rifaximin or fidaxomicin for 2 to 3
weeks. The specific clinical characteristics of patients
involved in this study are summarized in Additional
file 5: Table S2.
Fecal microbiota transplantation
FMT was done using a standardized preparation of con-
centrated fresh or frozen fecal bacteria via colonoscopy
as previously described [18]. All patients were treated
with oral vancomycin, 125 mg four times daily, until 2
days prior to the procedure [18]. The day before the pro-
cedure, patients received a polyethylene glycol-basedcolonoscopy prep (GoLYTELY® or MoviPrep®) to remove
residual antibiotics and fecal material. Donor fecal
microbiota was placed into the terminal ileum and/or
cecum via the biopsy channel of the colonoscope. A
total of 17 donor samples from the same individual were
used in these studies. The CD1 to CD4 donor samples
were given to patients CD1 to CD4, respectively. Pa-
tients CD1, CD3, and CD4 received freshly prepared
fecal microbiota, while patient CD2 received a previously
frozen preparation of fecal microbiota, all from the same
standardized, anonymous donor.
Sample collection
Fecal samples were collected at home by the patients
using swabs to sample feces deposited into a toilet hat
immediately after production and stored frozen at
approximately −20°C. Samples were subsequently trans-
ferred to the laboratory and stored at −80°C until used.
Donor samples for DNA extraction were collected during
processing of material for FMTand stored frozen at −80°C
until used. Samples from patients CD1 to CD4 were
obtained prior to FMT and between 1 to 151 days
post-FMT, with daily collection until day 28, and weekly
collection until day 84. Fecal material prior to FMT was
obtained from patients CD5 to CD14.
DNA extraction
DNA was extracted from donor and recipients’ pre- and
post-FMT fecal samples using MOBIO PowerSoil DNA
extraction kits (MOBIO, Carlsbad, CA, USA), according
to the manufacturer’s instructions. Fecal DNA concen-
trations were measured using a QuBit DNA quantifica-
tion system (Invitrogen, Carlsbad, CA, USA).
PCR amplification
Extracted DNA was amplified using the EMP standard
protocols at http://www.earthmicrobiome.org/ following
the recommendations of Caporaso et al. [26]. Briefly,
F515/R806 primers were used, with 12-base Golay codes
introduced on the 806 end to provide unique sample
indices. Cycling and annealing conditions were as previ-
ously described [26].
DNA sequencing
DNA sequencing was performed as previously described
[26] on an Illumina MiSeq platform using 2 × 150 bp
paired-end reads and the Illumina v3 reagent chemistry.
Sequence processing and analysis
Sequence data was processed and analyzed using QIIME
[21] according to the Illumina demultiplexing and pro-
cessing protocol [26] and current quality-filtering recom-
mendations [27], using the 1.8.0 pipeline and the default
parameters in split_libraries_fastq.py. After quality control
Weingarden et al. Microbiome  (2015) 3:10 Page 7 of 8and demultiplexing, we picked close references at 97%
similarity against the 97% similarity Greengenes data-
base [28] version 13_8. All further analyses were per-
formed at a rarefied depth of 5,000 reads/sample.
EMPeror [29] was used for data visualization of BIOM-
format [30] OTU tables. OTU analyses were performed
by clustering at the 97% level with UCLUST [31],
and data were integrated with the HMP dataset accord-
ing to the protocols used for similar previous meta-
analyses [15,32]. Sequences were analyzed by using
both weighted and unweighted UniFrac [32], followed
by principal coordinate analysis [21]. Data were visual-
ized using Phinch. The Phinch program provides an
easy-to-use, browser-based, platform to visualize con-
tingency tables along with their sample metadata (Bik
et al., manuscript in preparation, https://github.com/
PitchInteractiveInc/Phinch).Analysis of microbiome stability and centrality
For each set of post-transplant patient samples, we
assessed the similarity of that set to the set of reference
samples from the donor (2,000 reads/sample). To
reduce noise and compare patient samples along only
relevant dimensions in UniFrac distance space, we
applied PCoA to the unweighted UniFrac distance
matrix containing only the post-transplant and donor
samples for that donor-patient pair, then recalculated
the distances using only the first n principal coordi-
nates axes required to explain at least 80% of the vari-
ation in the distance matrix. An 80% cutoff was chosen
to balance bias and overfitting. Distances were recalcu-
lated using Euclidean distances between points in
PCoA space in order to convert PCoA coordinates to
a distance matrix. The empirical P values for the ‘nor-
mality’ were obtained by comparing the mean distance
between patient and donor samples to the histogram of
within-donor distances (generated using all samples
from a given donor by enumerating the pairwise dis-
tance between those samples). The empirical P values
for the ‘dynamic range’ (stability) were obtained by
comparing the mean distance within patient samples to
the histogram of within-donor distances. These ana-
lyses were also performed using alternative parameters
including, weighted UniFrac, Jensen-Shannon, root
Jensen-Shannon, and Bray-Curtis.Consent
Approval for this study was given by the University of
Minnesota Institutional Review Board (Protocol Number:
0901M56962). All human subjects provided informed
consent for participation in the study and collection and
analysis of data. All human subjects gave their permission
for their information to be published.Additional files
Additional file 1: Movie supplement. An animated visualization of
FMT-associated changes in patients’ fecal microbial communities.
Additional file 2: Figure S1. Microbial communities remain dynamic
after FMT. (A) Unweighted and (B) weighted UniFrac analyses, followed
by principal component analysis of bacterial communities of recurrent
CDI patient fecal samples, by time point after FMT and donor samples
(blue). PC: principal component. Percentages represent percent variability
explained by each principal component. See key at right for colors
associated with samples from patients after FMT (CD1-CD4).
Additional file 3: Table S1. OTU table.
Additional file 4: Figure S2. Pearson and Spearman correlations
between fecal communities before and after FMT for all collected fecal
samples. Heat maps indicating Pearson (left) and Spearman (right)
correlation values between respective donor and pre- or post-FMT fecal
microbial communities of patients.
Additional file 5: Table S2. Clinical metadata of patients used in this study.
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